Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Soiken HoldingsTSE:2385 -1.36%57 EBITDA Margin % is 11.54% as of Mar. 2026, which is 41% above its 10-year median of 8.18. GuruFocus rates TSE:2385 with a GF Score™ of 57/100 and a GF Value™ of 円118.45 (Significantly Overvalued). The stock has 1 warning sign investors should review. Among 944 Biotechnology companies, Soiken Holdings ranks better than 71.29% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Soiken Holdings's EBITDA for the
three
months ended in Mar. 2026 was 円95 Mil. Soiken Holdings's Revenue for the
three
months ended in Mar. 2026 was 円822 Mil. Therefore, Soiken Holdings's EBITDA margin for the quarter that ended in Mar. 2026 was 11.54%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Soiken Holdings EBITDA Margin % Related Terms
Soiken Holdings EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Soiken Holdings's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:2385 vs VRTX, REGN, RVMD: EBITDA Margin % Comparison
For the Biotechnology subindustry, Soiken Holdings's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Soiken Holdings EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Soiken Holdings's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Soiken Holdings's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Soiken Holdings (TSE:2385) has a EBITDA Margin % of 11.54% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Soiken Holdings and its competitors. This is 41% above median its historical median of 8.18. According to the industry distribution chart, Soiken Holdings ranks #271 out of 944 companies in the Biotechnology industry, placing it in the top 28.7%.
Is Soiken Holdings' EBITDA Margin % too high?
Soiken Holdings' current EBITDA Margin % of 11.54% is 41% above median its 10-year median of 8.18. Based on the distribution chart, Soiken Holdings ranks #271 out of 944 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Soiken Holdings has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Soiken Holdings' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Soiken Holdings ranks #271 out of 944 companies for EBITDA Margin %. This puts Soiken Holdings in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Soiken Holdings and its competitors. Soiken Holdings's current EBITDA Margin % is 11.54%, which is 41% above median its own 10-year median of 8.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Soiken Holdings stock overvalued right now?
Based on GuruFocus' analysis, Soiken Holdings (TSE:2385) is currently considered Significantly Overvalued. The stock's GF Value™ is 円118.45, compared to a current price of 円218.00 — trading 84% above its estimated fair value. The current EBITDA Margin % is 11.54%, which is 41% above median its 10-year median of 8.18. Soiken Holdings' overall GF Score™ is 57/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Soiken Holdings (TSE:2385), the current EBITDA Margin % is 11.54% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Soiken Holdings (TSE:2385) Overvalued in 2026?
Based on GuruFocus' analysis, Soiken Holdings stock appears to be overvalued.
The current stock price of 円218.00 is trading 84% above its estimated GF Value™ of 円118.45.
GuruFocus considers Soiken Holdings to be Significantly Overvalued.
Key valuation signals for TSE:2385:
EBITDA Margin %: 11.54% (41% above median its 10-year median of 8.18)
GF Value™: 円118.45 vs. price of 円218.00 (84% above fair value)
No single metric tells the full story. See the TSE:2385 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Soiken Holdings Inc operates as a biotechnology company in Japan. It provides clinical testing for pharmaceutical and food manufacturers that develop drugs and health food products based on biomarkers. It is involved in the marketing research and post-marketing surveillance of health supplements.
57GF Score
Get the complete analysis for TSE:2385
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:2385 has been successfully added to your 
